Pharmacy

The FINANCIAL -- Gilead Sciences, Inc. on February 7 announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 ...

More Articles ...

More Articles ...

The FINANCIAL -- Commenting on the Group’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and ...

The FINANCIAL -- Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, entered into a definitive agreement under which Sanofi will offer to acquire ...

The FINANCIAL -- Gilead Sciences, Inc. announced on February 6 its results of operations for the fourth quarter and full year ...

The FINANCIAL -- Merck known as MSD outside the United States and Canada, on February 2 announced financial results for the fourth quarter and full year of ...

Videos

Watch the video